LivaNova PLC ((LIVN)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
LivaNova PLC’s latest earnings call struck an upbeat tone, as management highlighted double-digit top-line growth, upgraded full-year guidance and a string of regulatory and clinical wins. While acknowledging near-term pressure on cash flow, margins and supply, executives emphasized that investments in manufacturing capacity and R&D are positioning the company for sustained, profitable growth.
Top-Line Growth and Upgraded 2026 Revenue Guidance
LivaNova reported Q1 2026 revenue of $362 million, up 11% year over year on a constant-currency basis, driven by strength across its core franchises. Management lifted full-year 2026 revenue growth guidance to 7%–8% from 6%–7%, signaling confidence that demand trends will remain robust despite ongoing macro and operational headwinds.
Cardiopulmonary Segment Strength
The cardiopulmonary business remained the company’s workhorse with Q1 revenue of $209 million, rising 14% versus the prior year. Heart-lung machine sales grew in the high teens and consumables in the mid-teens, prompting LivaNova to raise its 2026 cardiopulmonary revenue growth outlook to 8.5%–9.5% from 7%–8%.
Essenz Upgrade Momentum and Manufacturing Upside
Adoption of the Essenz heart-lung system is accelerating, with management expecting it to account for about 80% of annual placements in 2026 versus roughly 55% in 2025. To meet demand, LivaNova plans to increase manufacturing output at a low double-digit rate next year and bring a new oxygenator manufacturing line online in the second half of 2026.
Epilepsy Business Acceleration and Reimbursement Win
Epilepsy revenue rose 8% in Q1, with Europe and the rest of world up 12% and the U.S. up 7%, underscoring a broad-based growth trend. A major lift came from U.S. Medicare, which sharply increased outpatient payments for VNS implants and end-of-service procedures, leading management to raise epilepsy revenue guidance to 6%–7% from 5.5%–6.5%.
Regulatory and Clinical Milestones in OSA
In obstructive sleep apnea, LivaNova secured FDA premarket approval for its aura6000 system, which stands out as the first hypoglossal nerve stimulation device cleared without certain CCC-related limitations. The approval was reinforced by publication of full 12-month results from the OSPREY randomized trial, showing clinically meaningful and sustained benefits for patients.
PolySync Efficacy and Clinical Differentiation
The company spotlighted its PolySync titration algorithm, which converted more than half of OSPREY nonresponders into responders. With the cumulative responder rate approaching roughly 80% in the trial after PolySync use, management argued the technology provides clear clinical differentiation as LivaNova prepares to enter a competitive OSA market.
Improved Profitability Metrics and EPS Upgrade
Profitability metrics moved higher, with adjusted operating income rising to $71 million from $65 million and Q1 adjusted operating margin hitting about 20%. Adjusted diluted EPS climbed to $0.98 from $0.88, and the company raised its 2026 adjusted EPS outlook to $4.20–$4.30, implying around 9% growth at the midpoint.
Balance Sheet Improvements and Debt Reduction
LivaNova exited the quarter with $540 million in cash and reduced total debt to $288 million from $377 million at year-end 2025. The improvement reflects early repayment of $98 million in term facilities, which tightens near-term liquidity but lowers future interest expense and leaves the balance sheet in a stronger position.
Adjusted Free Cash Flow and Cash Decrease in Q1
Adjusted free cash flow came in at $4 million versus $20 million a year earlier, and the cash balance fell from $636 million to $540 million over the quarter. Management attributed the decline to early debt repayment, increased capital expenditure and a build in working capital, stressing that these moves are deliberate investments to support future growth.
Higher R&D and SG&A Dollars
Spending stepped up in strategic areas, with adjusted R&D rising to $47 million, or 13% of revenue, from $38 million, reflecting intensified investment in OSA and other pipeline programs. Adjusted SG&A increased to $129 million from $116 million, though efficiency gains kept SG&A as a percentage of revenue modestly lower at 36% versus 37%.
Adjusted Gross Margin Slightly Lower
Adjusted gross margin dipped to 68% from 69%, as favorable pricing and higher volumes could not fully offset currency headwinds and product mix shifts. Management suggested that while near-term margin pressure is real, the combination of scale, pricing discipline and manufacturing upgrades should help stabilize profitability over time.
Supply Constraints and Backorder Environment Persist
Despite expanding manufacturing efforts, demand for oxygenators continues to outstrip supply, leaving a backlog of orders. LivaNova noted that third-party component availability has improved, but further supplier gains are needed before the company can capture upside beyond what is already embedded in its guidance.
Market Access and Reimbursement Uncertainties for HGNS and DTTD
Management flagged ongoing uncertainty in reimbursement for hypoglossal nerve stimulation, which could influence the timing and pace of aura6000’s rollout. The company is similarly engaged with regulators on reimbursement for difficult-to-treat depression, but emphasized that the path and timing remain unclear and are not yet built into expectations.
External Macro and One-Time Impacts
External factors are also weighing on the outlook, with the Middle East conflict expected to trim adjusted operating income by about $5 million through higher shipping, logistics and fuel costs. Tariffs are forecast to have a net negative impact of under $5 million, and Q1 earnings were additionally burdened by a one-time payout of accrued bonuses for 2025.
Forward-Looking Guidance and Outlook
Looking ahead, LivaNova expects constant-currency revenue growth of 7%–8% in 2026 with an added tailwind from foreign exchange, powered by cardiopulmonary growth of 8.5%–9.5% and epilepsy growth of 6%–7%. The company is targeting an adjusted operating margin of 20%–21%, adjusted EPS of $4.20–$4.30 and adjusted free cash flow of $160 million–$180 million, even as it lifts capex by $40 million to fund capacity and product expansion.
LivaNova’s earnings call painted the picture of a company balancing strong operational momentum with calculated investments and manageable risks. Investors will see near-term cash and margin pressure as the price of upgrading manufacturing, accelerating R&D and navigating reimbursement uncertainty, but the raised guidance, debt reduction and rich pipeline suggest the growth story remains firmly intact.